/Companies

Fifth Eye

6 known investors

Find your way into Fifth Eye

Sign up to see every warm intro you have to Fifth Eye

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Fifth Eye team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Software that detects subtle vital-sign changes to warn medical professionals of post-operative patient deterioration risk.

Founders & leadership

JBJen Baird, NACD.DC
Jen Baird, NACD.DCFounderJen Baird is an NACD-certified board director with over two decades of experience founding and leading venture-backed startups as CEO, including companies that achieved FDA clearances and successful clinical deployments in healthcare technology. She currently serves on public, private, and non-profit boards and is active as a mentor and angel investor.
MSMark Salamango
Mark SalamangoFounderMark Salamango has worked for over 20 years in technology, strategy, and management roles, with experience in software architecture and government business development. He is founder of Fifth Eye, which develops software to detect vital-sign changes and alert medical professionals to post-operative patient deterioration risk.

Investors · 6

Also in the syndicate · 2

Biosciences Research and Commercialization CenterMINTS

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does Fifth Eye do?
Software that detects subtle vital-sign changes to warn medical professionals of post-operative patient deterioration risk.
Who founded Fifth Eye?
Fifth Eye was founded by Jen Baird, NACD.DC, Mark Salamango.
Who are Fifth Eye's investors?
Fifth Eye's investors include Invest Michigan, WMU Biosciences Research & Commercialization Center, Arboretum Ventures, Cultivation Capital.